WuXiAppTec buys UK’s Oxgene in all-cash takeover to get into US$2.6 billion global market for cell and gene therapy

• WuXiAppTec paid US$135 million cash for Oxgene, turning it into a wholly owned subsidiary of WuXi Advanced Therapies (ATU) for developing, manufacturing and testing biotech services
• Oxgene remains independent and will retain its brand name, led by Cawood